Glenmark Pharmaceuticals Limited has informed the Exchange regarding Cessation of Mr Rajesh Desai as Non- Executive Independent Director of the company w.e.f. Jun 25, 2025.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mr. Rajesh Desai (DIN: 00007960) will cease to be an Independent Director of Glenmark Pharmaceuticals with effect from June 25, 2025, due to the completion of his term. This is a routine, planned end-of-term exit and not a mid-term resignation. Following his departure, three board committees — Audit, Stakeholders Relationship, and Risk Management — have been reconstituted from June 26, 2025 using existing directors. No new appointments were announced as part of this intimation.
This is a routine board change with no operational impact on the company. Shareholders should not read this as negative; the company is simply moving on as the independent director's fixed term ends. Investors may want to track whether a replacement independent director is appointed soon to maintain board composition norms.